Viral Vector CDMO Services From Design To GMP Delivery

Scale-up risk in viral vector programs often starts well before the first GMP run, in construct design, plasmid quality, and the gaps between development, testing, and manufacturing. Minaris outlines how it approaches the full path from construct to clinical supply for lentiviral and AAV programs, in vivo and ex vivo. The coverage includes engineering technologies such as TESSA®, XOFLX®, and a clonal HEK293 cell line with a DMF, along with co-located testing and manufacturing, suspension capacity up to 1000L, and integrated fill-finish. It also notes the experience behind 80+ GMP viral vector batches delivered.

Explore the capabilities to see how the workflow is structured, and where client-owned processes fit alongside established platform options.